Nov-22-21 Upgrade William Blair
Mkt Perform → Outperform
Oct-07-21 Resumed Jefferies
Buy
$100
Sep-09-21 Upgrade Stifel
Hold → Buy
$86 → $96
Jun-04-21 Resumed Robert W. Baird
Outperform
$101
Apr-26-21 Resumed Credit Suisse
Outperform
$102
Mar-04-21 Resumed Guggenheim
Buy
Mar-01-21 Upgrade Evercore ISI
In-line → Outperform
$90 → $100
Aug-20-20 Downgrade William Blair
Outperform → Mkt Perform
Aug-20-20 Downgrade Citigroup
Buy → Neutral
$148 → $86
Aug-19-20 Downgrade Stifel
Buy → Hold
$127 → $100
Aug-19-20 Downgrade RBC Capital Mkts
Outperform → Sector Perform
Aug-19-20 Downgrade Evercore ISI
Outperform → In-line
Jul-08-20 Downgrade Morgan Stanley
Overweight → Equal-Weight
$125
Jul-06-20 Reiterated Citigroup
Buy
$105 → $148
Jan-28-20 Initiated BMO Capital Markets
Market Perform
Jan-27-20 Initiated BMO Capital Markets
Market Perform
Jan-24-20 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$111 → $113
Nov-27-19 Upgrade Barclays
Equal Weight → Overweight
$86 → $98
Nov-12-19 Initiated SunTrust
Buy
$110
Oct-17-19 Resumed BofA/Merrill
Buy
$90
Jan-20-22 09:38AM Jan-19-22 09:38AM 08:56AM Jan-14-22 04:51PM American City Business Journals
Jan-12-22 11:10AM 03:48AM Jan-10-22 08:34AM 07:55AM 06:29AM Jan-09-22 03:13PM Jan-04-22 05:08PM American City Business Journals
06:00AM Dec-31-21 06:18PM Dec-30-21 06:01PM 06:52AM Dec-29-21 06:01PM Dec-28-21 05:49PM Dec-27-21 09:38PM Dec-24-21 06:18PM Dec-22-21 08:42PM 06:15PM 04:20PM 04:00PM 11:00AM Dec-21-21 10:01PM 06:38PM 01:40PM 01:16PM 01:00PM 11:43AM 08:00AM Dec-20-21 05:29PM American City Business Journals
02:28PM 10:04AM 09:50AM 07:45AM Dec-19-21 09:36PM 08:24AM Dec-18-21 10:15AM Dec-17-21 06:18PM 05:38PM 04:10PM 12:00PM 08:00AM Dec-16-21 07:30PM 04:27PM 04:05PM 04:00PM 12:35PM 09:55AM 04:04AM Dec-15-21 09:57PM 07:20PM 06:15PM 04:05PM 01:20PM 07:45AM Dec-14-21 10:09PM 09:00PM 08:08PM 10:00AM 09:40AM 07:45AM Dec-13-21 06:38PM 05:38PM 01:20PM 08:35AM Dec-10-21 03:00PM 01:15PM 08:10AM Dec-09-21 09:00PM 04:30PM 11:00AM 07:45AM Dec-08-21 10:45AM 08:15AM Dec-07-21 05:13PM 02:15PM 01:26PM 12:18PM 11:00AM Dec-06-21 04:44PM 12:45PM Dec-05-21 11:42AM Dec-04-21 05:00AM Dec-03-21 07:56PM 06:32PM 11:30AM 11:00AM 08:35AM Dec-02-21 11:37PM 06:30PM 03:13PM 01:33PM 12:00PM 09:48AM 08:20AM Dec-01-21 08:07PM 06:29PM 09:49AM
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LAWLIS V BRYAN Director Jan 14 Option Exercise 37.46 4,250 159,205 28,220 Jan 19 06:34 PM LAWLIS V BRYAN Director Jan 14 Sale 87.61 4,250 372,342 23,970 Jan 19 06:34 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 13 Option Exercise 37.46 5,000 187,300 308,789 Jan 14 08:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 13 Sale 87.86 5,000 439,300 303,789 Jan 14 08:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 12 Option Exercise 37.46 5,000 187,300 308,789 Jan 14 08:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 12 Sale 89.00 5,000 445,000 303,789 Jan 14 08:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 16 Option Exercise 37.46 6,000 224,760 309,689 Dec 17 07:03 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 16 Sale 84.68 6,000 508,080 303,689 Dec 17 07:03 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 15 Option Exercise 37.46 6,000 224,760 309,689 Dec 17 07:03 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 15 Sale 82.71 6,000 496,260 303,689 Dec 17 07:03 PM BIENAIME JEAN JACQUES Chief Executive Officer Dec 01 Sale 87.22 1,500 130,832 304,389 Dec 02 09:42 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Oct 26 Sale 73.60 2,739 201,590 55,853 Oct 28 07:48 PM BIENAIME JEAN JACQUES Chief Executive Officer Oct 20 Option Exercise 37.46 1,000 37,460 305,839 Oct 22 04:36 PM Davis George Eric EVP, General Counsel Aug 02 Sale 76.69 5,518 423,175 58,590 Aug 04 04:59 PM BIENAIME JEAN JACQUES Chief Executive Officer Jun 21 Option Exercise 37.46 1,000 37,460 304,839 Jun 23 05:04 PM BIENAIME JEAN JACQUES Chief Executive Officer May 10 Option Exercise 26.49 8,513 225,509 312,352 May 12 07:21 PM BIENAIME JEAN JACQUES Chief Executive Officer May 10 Sale 77.29 8,513 657,970 303,839 May 12 07:21 PM Mueller Brian EVP, Chief Financial Officer May 07 Option Exercise 28.23 6,709 189,395 38,066 May 11 07:42 PM BIENAIME JEAN JACQUES Chief Executive Officer May 07 Option Exercise 26.49 25,000 662,250 328,839 May 10 09:07 PM BIENAIME JEAN JACQUES Chief Executive Officer May 07 Sale 78.12 25,000 1,953,121 303,839 May 10 09:07 PM Mueller Brian EVP, Chief Financial Officer May 07 Sale 79.50 6,709 533,366 31,357 May 11 07:42 PM MEIER RICHARD A Director May 06 Option Exercise 26.49 15,000 397,350 99,340 May 07 07:48 PM BIENAIME JEAN JACQUES Chief Executive Officer May 06 Option Exercise 26.49 25,000 662,250 328,839 May 10 09:07 PM BIENAIME JEAN JACQUES Chief Executive Officer May 06 Sale 78.29 25,000 1,957,199 303,839 May 10 09:07 PM MEIER RICHARD A Director May 06 Sale 78.38 5,068 397,245 94,272 May 07 07:48 PM Davis George Eric EVP, General Counsel May 03 Sale 78.30 4,673 365,896 64,108 May 04 08:27 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 30 Option Exercise 37.46 1,000 37,460 303,498 May 03 08:24 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 23 Option Exercise 26.49 10,000 264,900 312,498 Apr 26 08:44 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 23 Sale 79.34 10,000 793,400 302,498 Apr 26 08:44 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 22 Option Exercise 26.49 10,000 264,900 312,498 Apr 26 08:44 PM BIENAIME JEAN JACQUES Chief Executive Officer Apr 22 Sale 78.91 10,000 789,100 302,498 Apr 26 08:44 PM Davis George Eric EVP, General Counsel Apr 19 Option Exercise 26.49 2,709 71,761 71,149 Apr 20 09:53 PM Davis George Eric EVP, General Counsel Apr 19 Sale 79.58 2,709 215,582 68,440 Apr 20 09:53 PM LAWLIS V BRYAN Director Apr 15 Option Exercise 26.49 7,500 198,675 26,350 Apr 19 04:09 PM LAWLIS V BRYAN Director Apr 15 Sale 76.90 7,500 576,750 18,850 Apr 19 04:09 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Apr 08 Sale 78.81 1,537 121,131 58,250 Apr 09 05:57 PM Mueller Brian EVP, Chief Financial Officer Apr 01 Sale 76.30 5,692 434,300 31,016 Apr 02 07:35 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 24 Sale 76.30 1,181 90,110 61,439 Mar 26 05:45 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 18 Sale 77.99 1,308 102,011 64,133 Mar 19 09:01 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 12 Option Exercise 26.49 7,000 185,430 302,652 Mar 15 08:26 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 12 Sale 77.10 7,000 539,700 295,652 Mar 15 08:26 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 11 Option Exercise 26.49 7,000 185,430 302,652 Mar 15 08:26 PM BIENAIME JEAN JACQUES Chief Executive Officer Mar 11 Sale 77.68 7,000 543,760 295,652 Mar 15 08:26 PM GREY MICHAEL G Director Mar 05 Option Exercise 26.49 5,000 132,450 47,840 Mar 09 05:59 PM GREY MICHAEL G Director Mar 05 Sale 76.28 5,000 381,400 42,840 Mar 09 05:59 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 19 Option Exercise 26.49 7,000 185,430 302,552 Feb 22 08:38 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 19 Sale 83.58 7,000 585,060 295,552 Feb 22 08:38 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 18 Option Exercise 26.49 7,000 185,430 302,552 Feb 19 09:22 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 18 Sale 85.08 7,000 595,560 295,552 Feb 19 09:22 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 17 Option Exercise 26.49 8,000 211,920 303,552 Feb 18 09:45 PM BIENAIME JEAN JACQUES Chief Executive Officer Feb 17 Sale 84.54 8,000 676,320 295,552 Feb 18 09:45 PM LAWLIS V BRYAN Director Feb 16 Option Exercise 26.49 7,500 198,675 26,350 Feb 18 06:43 PM LAWLIS V BRYAN Director Feb 16 Sale 87.41 7,500 655,575 18,850 Feb 18 06:43 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 29 Option Exercise 26.49 8,334 220,768 303,886 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 29 Sale 82.67 8,334 688,972 295,552 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 28 Option Exercise 26.49 8,333 220,741 303,885 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 28 Sale 82.91 8,333 690,889 295,552 Feb 01 07:00 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 27 Option Exercise 26.49 8,333 220,741 303,885 Jan 28 07:35 PM BIENAIME JEAN JACQUES Chief Executive Officer Jan 27 Sale 85.49 8,333 712,388 295,552 Jan 28 07:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
